Patent intelligence · US
US 8501727
Short acting benzothiazepine calcium channel blockers and uses thereof
Short acting benzothiazepine calcium channel blockers and uses thereof
Patent details — US 8501727
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 6, 2013
- Expiration
- Aug 1, 2033
- Applicant
- Milestone Pharmaceuticals Inc.
- Claims
- 28
- CPC classes
- A61K, A61K31/554, A61P, A61P7/00
Quick answer
US 8501727 (Short acting benzothiazepine calcium channel blockers and uses thereof) is held by Milestone Pharmaceuticals Inc.. Status: granted. Granted Aug 6, 2013. Expires Aug 1, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Milestone Pharmaceuticals Inc.
- Grant date
- Expiration
- Claims
- 28
- CPC classes
- A61K, A61K31/554, A61P, A61P7/00, A61P9/10, A61P9/12
More from Milestone Pharmaceuticals Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12257224
Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker
granted -
US 10632255
Drug infusion device
granted -
US 10308609
Bicyclic compounds
granted -
US 10251851
Bicyclic analgesic compounds
granted -
US 10117848
Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof
granted -
US 10010524
Short acting phenylalkylamine calcium channel blockers and uses thereof
granted -
US 10010523
Short acting phenylalkylamine calcium channel blockers and uses thereof
granted -
US 10010522
Short acting phenylalkylamine calcium channel blockers and uses thereof
granted
Frequently asked questions
What is US patent 8501727?
US 8501727 (Short acting benzothiazepine calcium channel blockers and uses thereof) is held by Milestone Pharmaceuticals Inc.. Status: granted. Granted Aug 6, 2013. Expires Aug 1, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8501727?
Milestone Pharmaceuticals Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 8501727 expire?
Our index shows an expiration date of Aug 1, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.